Literature DB >> 33010565

Major depressive disorder increased risk of psoriasis: A propensity score matched cohort study.

Yi-Hsien Chen1, Wei-Ming Wang1, I-Hsun Li2, Hui-Han Kao3, Chin-Bin Yeh4, Li-Ting Kao5.   

Abstract

BACKGROUND: Reports showed that elevated proinflammatory cytokines, as detected in patients with psoriasis, was noted in individuals with major depressive disorder (MDD). Therefore, this study aimed to clarify the association of MDD and prospective incidence of psoriasis in human using a nationwide study.
METHOD: This population-based cohort study used the data from the Taiwan National Health Insurance system. 64,486 patients were defined as MDD cohort and 64,486 propensity score matched subjects without MDD were identified as comparison cohort. Each patient was independently tracked for a 5-year study period to assure them for a psoriasis diagnosis after the index date. Stratified Cox proportional hazard models were used to calculate the hazard ratio (HRs) for 5-year psoriasis risk.
RESULTS: After adjustments, the HR of psoriasis for MDD patients was 1.32 compared with subjects without MDD. The stratified analyses present that MDD patients had approximately 1.30-fold significantly higher risk of psoriasis than comparison subjects in most subgroups. Furthermore, compared with the matched subjects without MDD, the adjusted HRs of psoriasis in the 2-, 3-, 4- and 5-year study periods were 1.33, 1.32, 1.33 and 1.32, respectively. LIMITATIONS: Several patients with MDD or psoriasis might not include in this study, because of using a medical claims database.
CONCLUSIONS: This study provides population-based evidence that MDD is an independent risk factor of developing psoriasis, with an increased risk in the male sex. Additional investigations verifying our findings and exploring possible pathological mechanisms would be of great interest and value to the psychiatric field.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Depression; Major depressive disorder; Psoriasis; Skin

Mesh:

Year:  2020        PMID: 33010565     DOI: 10.1016/j.jad.2020.09.108

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

Review 1.  Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review.

Authors:  Jin Bu; Ruilian Ding; Liangjia Zhou; Xiangming Chen; Erxia Shen
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

2.  Cognitive Functions Associated with Brain Imaging Markers in Patients with Psoriasis.

Authors:  Luiza Marek-Jozefowicz; Adam Lemanowicz; Małgorzata Grochocka; Monika Wróblewska; Katarzyna Białczyk; Katarzyna Piec; Grzegorz M Kozera; Zbigniew Serafin; Rafał Czajkowski; Alina Borkowska
Journal:  Int J Environ Res Public Health       Date:  2022-05-07       Impact factor: 4.614

3.  Serum 5-Hydroxytryptamine is Related to Psoriasis Severity in Patients with Comorbid Anxiety or Depression.

Authors:  Minxue Shen; Duling Cao; Yi Xiao; Yehong Kuang; Danrong Jing; Yajia Li; Panpan Liu; Xiang Chen; Wu Zhu
Journal:  Acta Derm Venereol       Date:  2021-08-16       Impact factor: 3.875

4.  Effect of cognitive behavioral therapy on anxiety and depression in patients with psoriasis: A protocol for systematic review and meta-analysis.

Authors:  Chuan Tan; Jianmei Jiang; Xiaoling Deng; Wei Xiang; Tingting Hu
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

5.  Influence of Indoor Temperature Exposure on Emergency Department Visits Due to Infectious and Non-Infectious Respiratory Diseases for Older People.

Authors:  Chien-Cheng Jung; Nai-Tzu Chen; Ying-Fang Hsia; Nai-Yun Hsu; Huey-Jen Su
Journal:  Int J Environ Res Public Health       Date:  2021-05-15       Impact factor: 3.390

Review 6.  The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects.

Authors:  Luiza Marek-Jozefowicz; Rafał Czajkowski; Alina Borkowska; Bogusław Nedoszytko; Michał A Żmijewski; Wiesław J Cubała; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.